David Lebovitz Analyst PerformanceAnalyst at CitigroupDavid Lebovitz is a stock analyst at Citigroup in the medical sector, covering 14 publicly traded companies. Over the past year, David Lebovitz has issued 2 stock ratings, including and buy recommendations. While full access to David Lebovitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Lebovitz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings35 Last 8 YearsBuy Recommendations29.41% 10 Buy RatingsCompanies Covered14 Unique Companies Ratings Distribution34RatingsDistribution of strong buy, buy, hold, and sell ratings by David Lebovitz.RatingPercentageCount Strong Buy0.0%0 ratings Buy29.4%10 ratings Hold64.7%22 ratings Sell5.9%2 ratingsOut of 34 total stock ratings issued by David Lebovitz at Citigroup, the majority (64.7%) have been Hold recommendations, followed by 29.4% Buy and 5.9% Sell.Best & Worst CallsBest Call000.0%SRPTMar 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%KPTINov 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ14 companiesDavid Lebovitz, an analyst at Citigroup, currently covers 14 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies100.0%David Lebovitz of Citigroup specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE7 companies50.0%MED - DRUGS5 companies35.7%MEDICAL INFO SYS1 company7.1%MED PRODUCTS1 company7.1% David Lebovitz's Ratings History at Citigroup Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsALNYAlnylam Pharmaceuticals9/2/2025Boost Price Target$450.26$583.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/11/2025Boost Price Target$315.85$404.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical5/2/2025Lower Price Target$62.03$78.00Neutral$00.0000.00% ROIALNYAlnylam Pharmaceuticals3/21/2025Boost Price Target$280.77$351.00Buy$000.0000.00% ROIMDGLMadrigal Pharmaceuticals2/27/2025Boost Price Target$340.91$469.00Buy$000.0000.00% ROIBMRNBioMarin Pharmaceutical2/20/2025Boost Price Target$68.80$82.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
